Aventis Divests Azmacort For $200 Mil.; Kos To Back Relaunch With 500 Reps
Executive Summary
Kos Pharmaceuticals will relaunch Azmacort with a 490-representative sales force following its $200 mil. purchase of the inhaled corticosteroid from Aventis